skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Which of the mentioned companies would you buy today (and why) for a long term rrsp hold? Thanks for all your advice.
Read Answer Asked by Darby on March 12, 2018
Q: Hello 5i
Please give me your thoughts on the above companies with regard to growth over the next 12-24 months. Which would you prefer?
Thank you so much for all your invaluable guidance!!
Dave
Read Answer Asked by Dave on March 12, 2018
Q: I have a well diversified CND and US portfolio. I have some US cash to deploy and currently own BAC, BIIB, GOOGL, AAPL, DWDP, FLIR, MS, SWKS and PYPL. I have a high risk tolerance and am looking for growth vs income. What would you top 3 US names be in order and what is your rational for the 3 picks. Thank you - Your advice has helped me become a better investor, GREAT service.
Scott
Read Answer Asked by Scott on March 12, 2018
Q: According to BloombergBusinessWeek , Cigna’s offer to buy ESRX.us includes $15 billion in debt, and Cigna will pay $48.75 in cash plus 0.2434 shares per Express Scripts share. That is approximately $96.03 per share , says Bloomberg. Yet in the past 2 days (8 and midday 9 March) ESRX shares have traded in the range US$79 – 85. This is noticeably lower than the offer valued at $96.

Do you see this as an opportunity to buy more ESRX? Or should an ESRX holder just wait and see? OR, do you think it is best to manage risk and sell ---even if price is 10 to 15% below current offer from Cigna. Is deal risk higher than most on this offer, given upheavels seen by pharmacy benefits managers and pharma chains like CVS?
Read Answer Asked by Adam on March 12, 2018
Q: Good morning 5i

I have benefited quite well from the ten year market performance. Not as well as if I had bought the US Market on March 9 2009 and added new capital all the way. In some individual stock positions I have experienced losses during this longest bull market run.

Additionally, over the past couple years, 5i has add positively to net asset value and this investor's awareness level.

The question here is about seeing through an inevitable correction or bear market event.
The minor correction event of 2018 offered a view to how it will feel when prices decline.
In the wake of that event, how does an investor continue to deploy and redeploy capital while staring at the high potential for a market decline.
The difficulty being experienced is, as I cleanup and balance individual weighting, it is now difficult to make a go-forward redeployment decision......add to equity exposure.
Additionally, the amount of time being waisted watching daily price movements has increased.
Some days it feels like going to cash would solve all my concerns. It would not however since asset growth is a necessary target.

From your experience would you please offer some Thoughts and guidance on what is written above?

Thanks
Dave



Read Answer Asked by David on March 12, 2018
Q: You have said in the past that New Highs tend to go higher. Is buying New Highs a good strategy ? Recent New Highs are GIB.A, TSGI, ZBK, PBL, TD, CSU, SHOP, CF, all good names and you seem positive towards these Companies. RAK
Read Answer Asked by bob on March 12, 2018
Q: Som seif recently said he predicts emerging block chain technology will cause the etf industry to go to zero. Do you consider this a feasible scenario and if so how imminent is this likely to occur in your opinion.
Read Answer Asked by Vicki L on March 12, 2018
Q: Gentlemen,
On my sector staple 7.7% PF, I have ATD.a (5.2% PF, +30%) & PBH (2.5%, +55%)
I wish to reduce the sector to 5%.
What 5IR suggest to reduce the 2.7% on this sector.
Thanks
best Regards
Read Answer Asked by Djamel on March 12, 2018
Q: In Nov IRO.v reported TTM EPS of $0.11USD for Q3 & it closed on Friday at $0.485. It appears to be extremely cheap with a P/E of roughly 3x. Fundamentals have been improving each quarter. They have some debt from the transformational acquisition of Papillon in 2016 but have been paying it down rapidly in 2017. With these key points above, I think it deserves some further consideration.

Another subscriber had asked about IRO in January & 5i said “At less than $10M market cap, we would completely avoid IRO.” Yes I agree, it’s a very illiquid microcap but that does not concern me because I’m not buying million of shares. I recently purchased a few thousand shares in my TFSA account. I thought it has potential to be a 4bagger this yr. Do you really think it should be avoid & why?
Read Answer Asked by David on March 12, 2018
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!